Summary & Overview
CPT 90997: Charcoal or Resin Hemoperfusion for Toxin Removal
CPT code 90997 designates extracorporeal hemoperfusion using charcoal or resin cartridges to remove toxins, drugs, or other substances from the blood. Clinically, it serves as an artificial detoxification process akin to an artificial kidney and is used for urgent, potentially life‑threatening poisonings as well as for select patients with renal failure. Nationally, the code matters because it represents a high-acuity, resource‑intensive intervention that intersects emergency medicine, nephrology, and toxicology.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise account of the clinical context for use of 90997, typical sites of service, common billing modifiers associated with high‑acuity procedures, and where available, benchmarks and coding considerations relevant to payer coverage and claim adjudication. The publication also outlines policy and billing nuances that affect reimbursement pathways and documentation expectations at a national level.
This summary equips clinicians, coding professionals, and policy analysts with a focused overview of CPT code 90997, clarifying its clinical role, payer landscape, and the types of information that affect payment and utilization review.
Billing Code Overview
CPT code 90997 describes an extracorporeal blood treatment that removes substances from the blood using a charcoal or resin cartridge functioning like an artificial kidney. This process is used to eliminate toxins or drugs from the bloodstream and can be employed for life‑threatening drug overdoses in patients with or without renal failure.
-
Service type: Extracorporeal blood detoxification using charcoal or resin hemoperfusion
-
Typical site of service: Hospital inpatient or hospital outpatient settings where critical toxin removal is required; may also occur in emergency department or intensive care units depending on clinical need
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to the emergency department or inpatient unit with a life‑threatening drug overdose (for example, severe theophylline, carbamazepine, or lithium toxicity) or with refractory toxin accumulation despite supportive care. Initial evaluation includes airway, breathing, circulation stabilization, toxicology screening, serum drug levels, electrolyte assessment, and renal function tests. When consultation determines that extracorporeal charcoal or resin hemoperfusion is indicated to remove the offending substance from the blood, vascular access (typically a central venous catheter) is placed, the hemoperfusion cartridge is primed and anticoagulation is managed per protocol, and the patient is monitored continuously for hemodynamic and bleeding complications. Hemoperfusion may be performed in the emergency department, intensive care unit, or specialized dialysis/pheresis unit. The procedure may be ordered as a single urgent treatment or as serial treatments depending on clinical response and measured drug levels. Documentation should include indication, substance/toxin involved, timing of ingestion or exposure, informed consent when feasible, vascular access type, anticoagulation used, duration of cartridge use, vital sign monitoring, and patient response including post‑procedure drug levels when obtained.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default — no modifier | Use when no additional modifier applies |